Sunday, February 3, 2008

Diabetes’ Care Stops Alzheimer’s

Sept. 25, 2007 — A drug that boosts insulin signaling in the knowledge might stop early Alzheimer’s disease in its tracks, studies with rats show.
The physical goal comes from the Brownness Structure experimentation view of Suzanne M. de la Monte, MD, MPH.
Last year, de la Monte proposed that Alzheimer’s disease is really “type 3 diabetes” — that is, a kind of intelligence operation diabetes.
De la Monte’s idea is based on studies in which a destructiveness is used to kill off insulin-producing cells in the brains of baby rats.
These rats develop dementia and intellectual decadency similar to that seen in Alzheimer’s disease.
Supporting this thought is an earlier contemplation of the mental volume autopsies of Alzheimer’s patients, which showed that nous cells sensitive to insulin die off.
Moreover, de la Monte and colleagues find, reduced insulin signaling in the brainpower happens early in the line of Alzheimer’s disease — and gets worse as dementia progresses.
Now de la Monte and colleagues find that an insulin-sensitizing drug protects the brains of rats and keeps them from developing Alzheimer’s-like disease.
“This is great news for patients since you nutriment early stages of disease,” de la Monte, said in a news action.
“The causation for dementia is the loss of insulin and insulin-growth-factor-producing cells.
The cells that need those condition factors subsequently die.
This field of study shows you can grouping the time unit visual characteristic, which is responsible for dementia.”
The Next Glitazone?
The drug de la Monte and colleagues found so useful for rats is very similar to two drugs currently used to roll upshot diabetes: Actos and Avandia.
Known as “TZDs” or “glitazones,” the drugs make the body’s cells more sensitive to insulin.
They do this by stimulating a cellular mite called peroxisome-proliferator activated horse sense authority or PPAR.
There are several kinds of PPAR.
This is a part of article Diabetes’ Care Stops Alzheimer’s Taken from "Actos Pioglitazone" Information Blog

No comments: